Bryan represents companies from a wide variety of disciplines in patent litigation matters and focuses on representing pharmaceutical companies in Hatch-Waxman litigation. Experienced in patent litigation, inter partes review proceedings and patent and trademark prosecution, Bryan counsels clients on the most efficient, effective and favorable way to resolve a dispute. Bryan’s Ph.D. and postdoctoral research involved biotechnology, molecular biology, biochemistry and studies of protein structure and signaling systems. In this arena, Bryan regularly defends some of the world’s largest pharmaceutical manufacturers in patent litigation involving drug substances, product formulations and methods of treating diseases and disorders. Bryan has extended this work beyond federal district court litigation, and has challenged pharmaceutical patents in inter partes review proceedings at the U.S. Patent and Trademark Office, including one of the first successful proceedings in this area.
Shannon focuses her practice on representing pharmaceutical and biotechnology clients in complex patent litigation. She has extensive experience trying large-scale patent litigation, nationally and internationally, relating to pharmaceutical patents and is currently lead trial counsel in several Hatch-Waxman cases. Shannon has represented clients before the U.S. Courts of Appeals for the Federal Circuit and the Third Circuit as well as numerous jurisdictions across the nation, including the District of Delaware, the District of New Jersey, the Southern District of New York, the Western District of Pennsylvania and the Western District of Wisconsin. She also has experience counseling pharmaceutical companies in their patent, patent litigation and regulatory strategies internationally. In the United States, Shannon has provided counseling on all aspects of the Hatch-Waxman Act and the Biologic Price Competition and Innovation Act.
Andrew focuses his practice on patent law, regularly practicing before the Patent Trial and Appeal Board and litigating patent matters before U.S. District Courts and the U.S. Court of Appeals for the Federal Circuit. His experience also includes advising clients in the pharmaceutical and biotechnology industries in obtaining patent protection for their inventions and assisting several higher education clients in preparing and filing U.S. and international patent applications for a variety of chemical and life sciences technologies. With a Ph.D. in molecular genetics and microbiology, Andrew uses his technical knowledge and experience to inform his counsel to clients in the pharmaceutical, biotechnology, and life sciences industries.
Emily represents clients in patent infringement suits in a range of technologies in district courts throughout the country, focusing her practice on pharmaceutical and biotechnology patent litigation. Emily also represents clients in inter partes reviews before the U.S. Patent and Trademark Office, again focusing her practice on the pharmaceutical industry. Emily also provides counseling on aspects of the Hatch-Waxman Act, as well as patent litigation strategies. Emily has a Master of Science degree in bacteriology and has extensive technical knowledge in molecular biology research and biotechnology.
Amy focuses on intellectual property matters including patent litigation, patent portfolio analysis and valuation, and AIA post grant procedures. Amy has extensive patent litigation experience involving a broad range of complex computer and electrical related technologies including computer networks, software, telecommunications and e-commerce. She has represented numerous Fortune 500 companies, international companies and emerging companies in a variety of federal jurisdictions. Amy is also lead counsel on 10 Inter Partes Review proceedings currently pending before the United States Patent Trial and Appeal Board (PTAB). Amy served as a judicial intern for the Honorable Paul Michel at the U.S. Court of Appeals for the Federal Circuit. In addition, Amy has authored numerous articles regarding recent trends in patent law and litigation, co-chaired patent monetization conferences and has been an invited guest speaker regarding portfolio analysis and valuation.
Michael’s practice focuses on patent litigation, post-grant patent proceedings, patent prosecution, global patent portfolio management, patent landscape assessments, freedom to operate and patent due diligence. Michael has been recognized by Intellectual Asset Management in the IAM Patent 1000, and by Chambers Global as a ‘Leading Lawyer’ highlighted as an “incredibly knowledgeable, extremely capable and very accessible” attorney. He has handled a wide variety of technical matters in biotechnology, pharmaceuticals, diagnostics and medical devices. For more than 15 years, Michael has been an active member of the Southern California Biomedical Council (SoCalBio) where he has served as the chair of the annual SoCalBio Investor Conference and is the secretary of the Board of Directors. He also regularly advises academic institutions, research institutions, emerging companies, privately held companies and publicly traded companies with respect to protecting and enforcing their intellectual property rights.